These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9102219

  • 21. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL.
    Cancer Res; 2002 Aug 01; 62(15):4263-72. PubMed ID: 12154028
    [Abstract] [Full Text] [Related]

  • 22. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
    Ning S, Trisler K, Wessels BW, Knox SJ.
    Cancer; 1997 Dec 15; 80(12 Suppl):2519-28. PubMed ID: 9406705
    [Abstract] [Full Text] [Related]

  • 23. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma.
    Zeng ZC, Tang ZY, Yang BH, Liu KD, Wu ZQ, Fan J, Qin LX, Sun HC, Zhou J, Jiang GL.
    Eur J Nucl Med Mol Imaging; 2002 Dec 15; 29(12):1657-68. PubMed ID: 12458401
    [Abstract] [Full Text] [Related]

  • 24. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.
    Kinuya S, Kawashima A, Yokoyama K, Koshida K, Konishi S, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.
    J Nucl Med; 2002 Aug 15; 43(8):1084-9. PubMed ID: 12163635
    [Abstract] [Full Text] [Related]

  • 25. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G, Booth BJ, Batra SK, Colcher D.
    Clin Cancer Res; 1999 Sep 15; 5(9):2613-9. PubMed ID: 10499640
    [Abstract] [Full Text] [Related]

  • 26. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A, Barbet J, Paris F, Kraeber-Bodéré F.
    Cancer; 2010 Feb 15; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [Abstract] [Full Text] [Related]

  • 27. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E, Kraeber-Bodéré F, Daniel L, Fiche M, Rouvier E, Saï-Maurel C, Thedrez P, Chatal JF, Barbet J.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [Abstract] [Full Text] [Related]

  • 28. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov 15; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 29. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
    Tschmelitsch J, Barendswaard E, Williams C, Yao TJ, Cohen AM, Old LJ, Welt S.
    Cancer Res; 1997 Jun 01; 57(11):2181-6. PubMed ID: 9187118
    [Abstract] [Full Text] [Related]

  • 30. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.
    Bioconjug Chem; 2005 Jun 01; 16(5):1117-25. PubMed ID: 16173788
    [Abstract] [Full Text] [Related]

  • 31. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.
    Cancer Res; 1997 Dec 01; 57(23):5309-19. PubMed ID: 9393755
    [Abstract] [Full Text] [Related]

  • 32. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [Abstract] [Full Text] [Related]

  • 33. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
    Kinuya S, Yokoyama K, Izumo M, Sorita T, Obata T, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N.
    Cancer Lett; 2005 Feb 28; 219(1):41-8. PubMed ID: 15694663
    [Abstract] [Full Text] [Related]

  • 34. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec 28; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

  • 35. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
    Siler K, Eggensperger D, Hand PH, Milenic DE, Miller LS, Houchens DP, Hinkle G, Schlom J.
    Biotechnol Ther; 1993 Dec 28; 4(3-4):163-81. PubMed ID: 8292968
    [Abstract] [Full Text] [Related]

  • 36. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
    Li L, Xu HY, Mi L, Bian HJ, Qin J, Xiong H, Feng Q, Wen N, Tian R, Xu LQ, Shen XM, Tang H, Chen ZN.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1238-44. PubMed ID: 16979831
    [Abstract] [Full Text] [Related]

  • 37. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy.
    Dearling JL, Qureshi U, Begent RH, Pedley RB.
    Clin Cancer Res; 2007 Mar 15; 13(6):1903-10. PubMed ID: 17363547
    [Abstract] [Full Text] [Related]

  • 38. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.
    J Nucl Med; 1997 Dec 15; 38(12):1944-50. PubMed ID: 9430475
    [Abstract] [Full Text] [Related]

  • 39. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
    Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL.
    Anticancer Res; 1998 Dec 15; 18(6A):4011-8. PubMed ID: 9891439
    [Abstract] [Full Text] [Related]

  • 40. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R, Juweid M, Zhang CH, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.